In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fresenius to acquire APP Pharmaceuticals for $3.7bn

Executive Summary

Germany's Fresenius SE (hospital, home care, and dialysis products) will pay $23 per share in cash (a 40% premium) to acquire all of the outstanding stock of US-based injectables manufacturer APP Pharmaceuticals. The deal is valued at about $3.7bn, plus the assumption of $940mm in debt, and the potential of an additional $970mm in sales-based earn-outs (what the companies refer to as "contingent value right").
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash

Related Companies